Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
• To assess the safety and tolerability of CDZ173 in patients with primary Sjögren’s syndrome. • To compare the effect of CDZ173 versus placebo on the patient-reported outcomes of primary Sjögren’s syndrome patients after 12 weeks of treatment (study week 13).
Critère d'inclusion
- Primary Sjögren’s syndrome